Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer—A Single Institution Experience With Long-Term Follow-Up

Kiura, Katsuyuki; Hayakawa, S.; Machitori, Y.; Shibata, Yukiko; Ogawa, Hiroaki; Ito, Kei; Shimizuguchi, T.; Kawamoto, Terufumi; Nihei, Keiji

doi:10.1177/1533033818806318

Cited by 15 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypofractionated schedules may be considered in these cases. Karasawa et al reported that accelerated hypofractionated radiotherapy with 75 Gy in 25 fractions at the isocenter, which is considered equivalent to 62.5 Gy in 25 fractions prescribed at PTV D95%, is promising in that it can achieve LC and survival results similar to SBRT, and it can control both central and peripheral stage I NSCLC without any serious organ toxicities [ 44 ].…”

Section: Differences According To the Primary Tumor: Non-lung Primary...mentioning

confidence: 99%

Stereotactic body radiation therapy for metastatic lung metastases

et al. 2022

View full text Add to dashboard Cite

Although systemic therapy is standard management for patients with metastatic disease, several recent reports have indicated that an addition of local therapies including stereotactic body radiation therapy (SBRT) for patients with oligometastatic disease (OMD) could improve survival. The lung is the most common site of distant metastasis from many solid tumors, and the strategy of SBRT, such as dose-fraction schedules, timing, etc., would be different depending on the type of primary tumor, location, and patterns of OMD. This review describes the role of SBRT with curative-intent for patients with pulmonary OMD for each of these variables. First, differences according to the type of primary tumor, for which many studies suggest that SBRT-mediated local control (LC) for patients with pulmonary OMD from colorectal cancer (CRC) is less successful than for those from non-CRC tumors. In addition, higher dose-fraction schedules seemed to correlate with higher LC; hence, different SBRT treatment strategies may be needed for patients with pulmonary OMD from CRC relative to other tumors. Second, differences according to location, where the safety of SBRT for peripheral pulmonary tumors has been relatively well established, but safety for central pulmonary tumors including pulmonary OMD is still considered controversial. To determine the optimal dose-fraction schedules, further data from prospective studies are still needed. Third, differences according to the patterns of OMD, the number of metastases and the timing of SBRT whereby 1–5 lesions in most patients and patients with synchronous or metachronous OMD are considered good candidates for SBRT. We conclude that there are still several problems in defining suitable indications for local therapy including SBRT, and that further prospective studies are required to resolve these issues.

show abstract

Section: Differences According To the Primary Tumor: Non-lung Primary...mentioning

confidence: 99%

Stereotactic body radiation therapy for metastatic lung metastases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…S PS 2005–2013 65 32/33 Both 71.8 Deep inspiration breath hold 4D-CT, MIP NR 50/–/50 4 NR LA, 6–12 CB or NCB NR 112.5/–/112.5/– 86 95.4 Cummings (2018) [ 23 ] U. S PS 2007–2015 65 98 30/35 44/54 NR 76 77 ITV > 0.5 cm: respiratory gating CTV = GTV, 4D-CT 5 30/–/30 50/50/40 1 5 1 fraction per day LA, 11 NCB No 120/120/–/– 100/100/72/86 24 40 84.0 82.8 karasawa (2018) [ 24 ] Japan RS 2003–2010 56 39/17 No 79 SBF Long-scan-time CT, margin 5 mm 5 48/48/42 4 Total 1 week LA, 6MV Yes 105.6/105.6/86.1/95.9 127 78.2 Ma (2018) [ 25 ] U. S RS 2007–2015 ...…”

Section: Resultsmentioning

confidence: 99%

“…At present, there is no uniform standard for the prescription dose method of SBRT. Some prescription doses are defined as isocenter dose [ 23 , 24 , 34 ], and some are defined as isodose lines surrounding 95% PTV volume [ 32 , 35 , 36 ]. At the same time, the degrees of heterogeneity of dose in PTV for different centers may be diverse.…”

Section: Discussionmentioning

confidence: 99%

Dose–effect relationship of stereotactic body radiotherapy in non-small cell lung cancer patients

Jiang

Mingwei

et al. 2022

Radiat Oncol

View full text Add to dashboard Cite

Objective To establish the dose effect relationship between the dose parameters of stereotactic body radiation therapy (SBRT) for early non-small cell lung cancer (NSCLC) and the local tumor control rate. Materials and methods A comprehensive literature search was conducted using PubMed, the Web of Science and the Cochrane databases to determine the articles treated with SBRT in early-stage NSCLC. Original studies with complete prescription dose information, tumor local control rate and other important parameters were screened and reported. Probit model in XLSTAT 2016 was used for regression analysis, and P < 0.05 was set as a statistically significant level. Results After literature screening, 22 eligible studies were included in probit model regression analysis, involving 1861 patients. There is no significant dose effect relationship between nominal BED10 and peripheral BED10 versus 3 years local control probability. There were significant dose effect relationships between the center BED10 and the average BED10 versus the 3 years local control probability, with P values are 0.001 and < 0.0001, respectively. According to the results of this model, the 3 years local control rate of 90.5% (87.5–92.1%) and 89.5% (86.7–91.0%) can be expected at the center BED10 of 180 Gy or the average BED10 of 140 Gy, prospectively. Conclusions For NSCLC treated with SBRT, more attention should be paid to the central dose and average dose of PTV. A set of clear definition in the dose prescription should be established to ensure the effectiveness and comparability of treatment.

show abstract

“…The normal tissues evaluated in this study are esophagus, aorta, heart, pulmonary artery, and trachea, and the D 1cc , D 5cc , D 10cc , and D 15cc of these organs were examined on the basis of previous clinical trials. 2 , 3 A total of 300 plans (20 cases × 3 MLC speed constraints × 5 error plans) were investigated.…”

Section: Methodsmentioning

confidence: 99%

“… 1 In general, SBRT is often performed on peripheral tumors, although some reports have described its use for central tumors. 2 , 3 In cases involving central lung tumors, the tumor is located in close proximity to the bronchi, heart, and great vessels, increasing the likelihood of toxicity. Thus, treatment planning with careful attention to these doses is essential in such cases.…”

Section: Introductionmentioning

confidence: 99%

Dosimetric Effects of Differences in Multi-Leaf Collimator Speed on SBRT-VMAT for Central Lung Cancer Patients

Saito

Komiyama

Marino

et al. 2022

Technol Cancer Res Treat

View full text Add to dashboard Cite

Purpose: We aimed to investigate the effects of different multi-leaf collimator (MLC) speed constraints in volumetric modulated radiotherapy (VMAT) on the robustness of treatment plans for central lung cancer patients. Method and Materials: Twenty patients with central lung tumor who underwent stereotactic body radiotherapy (SBRT) with the VMAT technique at our hospital were included in this retrospective study. The reference plans were created with 3 different MLC speed constraints (Plan A: 0.1 cm/deg., Plan B: 0.3 cm/deg., and Plan C: 0.5 cm/deg.) with a 50-Gy/8Fr, planning target volume (PTV) D95% prescription. In each of these plans, setup errors from 1 to 5 mm were intentionally added in the direction of the central organ at 1-mm intervals (300 plans [20 cases × 3 MLC speeds × 5 error plans] were created in total). Each plan was then calculated by the same beam conditions as each reference plan. The actual average MLC speed and dose difference between the reference plan and the error-added plan were then calculated and compared among the 3 MLC speeds. Results: In the reference plans, the actual average MLC speeds were 0.25 ± 0.04, 0.34 ± 0.07, and 0.39 ± 0.12 cm/deg. for Plan A, Plan B, and Plan C, respectively ( P < .05). For PTV and OARs, many dose indices tended to improve as the MLC speed increased, while no significant differences were observed among the 3 MLC speed constraints. However, in assessments of robustness, no significant differences in dose difference were observed among the 3 MLC speed constraints for most of the indices. Conclusions: When necessary, increasing the MLC speed constraint with a priority on improving the quality of the dose distribution is an acceptable approach for central lung cancer patients.

show abstract

Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer—A Single Institution Experience With Long-Term Follow-Up

Cited by 15 publications

References 22 publications

Stereotactic body radiation therapy for metastatic lung metastases

Stereotactic body radiation therapy for metastatic lung metastases

Dose–effect relationship of stereotactic body radiotherapy in non-small cell lung cancer patients

Dosimetric Effects of Differences in Multi-Leaf Collimator Speed on SBRT-VMAT for Central Lung Cancer Patients

Contact Info

Product

Resources

About